TipRanks on MSN
Tandem Diabetes resumed with a Hold at Stifel
Stifel resumed coverage of Tandem Diabetes (TNDM) with a Hold rating and $15 price target The firm is concerned about the company’s sequential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback